Linked Life Data

3044803

Source:http://linkedlifedata.com/resource/pubmed/id/3044803

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1988-10-3
pubmed:abstractText
We conducted a phase I trial with the combination carboplatin (CBDCA)-etoposide (VP-16) in thoracic cancer. CBDCA, at a starting dose of 300 mg/m2 dl, was associated with a fixed dose of VP-16 (100 mg/m2 dl-3). Escalation of doses was permitted after three patients entered at each dose level without grade IV toxicity. As expected, hematologic toxicity was the limiting factor. Severe myelosuppression (grade IV) occurred in three out of four patients treated at 350 mg/m2. Only three out of 19 patients treated at 325 mg/m2 exhibited a reversible grade IV hematologic toxicity. Other toxicities were mild and acceptable. Among 15 evaluable patients three showed a partial response. Two of the three responders have previously had a progression while receiving cisplatin and etoposide. The recommended dose of carboplatin to be associated with VP-16 (100 mg/m2 dl-3) is thus 325 mg/m2 dl.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0277-5379
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
963-7
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer.
pubmed:affiliation
Service de Médecine, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
pubmed:publicationType
Journal Article